|
18 Sep 2025 |
Cipla
|
Consensus Share Price Target
|
1559.60 |
1676.69 |
- |
7.51 |
buy
|
|
|
|
|
29 Jan 2024
|
Cipla
|
BOB Capital Markets Ltd.
|
1559.60
|
1576.00
|
1336.85
(16.66%)
|
Target met |
Buy
|
|
|
BJAUT: Healthy revival but priced in; downgrade to SELL. TVSL: On a fast track raise to BUY. SBICARD: Asset quality concerns persist; downgrade to HOLD. LAURUS: Challenges galore cut to SELL. CIPLA: Healthy revenue growth, strong margins. MAHGL: Volume growth accelerating, reiterate BUY. DCBB: NII sequentially flat on high interest cost. SBILIFE: ULIP-led growth; maintains market leadership
|
|
29 Jan 2024
|
Cipla
|
Axis Direct
|
1559.60
|
1515.00
|
1336.85
(16.66%)
|
Target met |
Buy
|
|
|
The company launching new products in the market. gSynbicort and one Peptide ($300-400 Mn) product have been already launched in the last quarter and the company has planned to launch 4 more peptides in FY25E.
|
|
26 Jan 2024
|
Cipla
|
Prabhudas Lilladhar
|
1559.60
|
1400.00
|
1369.65
(13.87%)
|
Target met |
Accumulate
|
|
|
|
|
25 Jan 2024
|
Cipla
|
BOB Capital Markets Ltd.
|
1559.60
|
1576.00
|
1369.65
(13.87%)
|
Target met |
Buy
|
|
|
Q3 strong with EBITDA beat of 9% over consensus, though impairment charges of Rs 1.9bn limited PAT outperformance vs consensus
|
|
25 Jan 2024
|
Cipla
|
SMC online
|
1559.60
|
|
1369.65
(13.87%)
|
|
Results Update
|
|
|
|
|
16 Jan 2024
|
Cipla
|
Motilal Oswal
|
1559.60
|
1540.00
|
1302.35
(19.75%)
|
Target met |
Buy
|
|
|
|
|
30 Oct 2023
|
Cipla
|
Axis Direct
|
1559.60
|
1350.00
|
1193.45
(30.68%)
|
Target met |
Buy
|
|
|
We have BUY on the stock
|
|
30 Oct 2023
|
Cipla
|
SMC online
|
1559.60
|
|
1193.45
(30.68%)
|
|
Results Update
|
|
|
|
|
28 Oct 2023
|
Cipla
|
ICICI Securities Limited
|
1559.60
|
1365.00
|
1174.25
(32.82%)
|
Target met |
Buy
|
|
|
Cipla continues to surprise us positively. Q2FY24 growth was led by core markets of India (up 10% YoY), US (~4% QoQ) and South Africa (15% YoY).
|
|
28 Oct 2023
|
Cipla
|
Prabhudas Lilladhar
|
1559.60
|
1350.00
|
1174.25
(32.82%)
|
Target met |
Buy
|
|
|
|